ASH: Vertex Positive Results from Pivotal Trials of CASGEVY

 Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced two oral presentations at the American Society of Hematology (ASH) Annual Meeting and Exposition from the global pivotal trials of CASGEVY™ (exagamglogene autotemcel [exa-cel]).

Data from 96 patients (44 sickle cell disease [SCD], 52 transfusion-dependent beta thalassemia [TDT]) treated with CASGEVY in pivotal studies, with the longest follow-up of more than four years, continue to reinforce the consistent and durable response to treatment. In addition, new data illustrating improvements in patient-reported outcomes after treatment with CASGEVY were featured in poster presentations at ASH.

https://www.biospace.com/article/releases/positive-results-from-pivotal-trials-of-casgevy-exagamglogene-autotemcel-highlighted-in-oral-presentations-at-the-american-society-of-hematology-ash-annual-meeting-and-exposition/